Cardiol's CardiolRx did not have a significant impact on left ventricular extracellular volume (LV-ECV) in the Phase II ARCHER study.

Lilly's orforglipron led to 12.4% weight loss after 72 weeks while Novo Nordisk’s oral GLP-1RA showed a 13.6% drop in weight.

The inaugural Outsourcing in Clinical Trials & Clinical Trial Supply China conference will gather experts to discuss China's rapidly evolving clinical research landscape.

The US FDA has cleared Starlight Therapeutics' IND for a Phase Ib/IIa trial assessing the combination of STAR-001.

The 2025 Clinical Trial Supply West Coast conference will gather experts to discuss US trial operations in a shifting tariff landscape.

A rise in gonorrhea infections had been predicted, but if the vaccine reaches vulnerable populations, these are now expected to decline.

Urogen's Zusduri is the first non-surgical therapy to be approved for NMIBC, setting a new standard for the indication.

SynOx Therapeutics has completed subject enrolment in its multi-centre Phase III TANGENT trial of emactuzumab for TGCT.

HMNC said a genetic subgroup of MDD patients benefited more from BH-200 in the Phase II trial, prompting Phase III plans.

Topline results of a Phase II trial reveal that VX-993 did not meet its primary endpoints, meaning Vertex will discontinue its development.

The World Health Organization (WHO) estimates that by early 2024, over 1,400 healthcare facilities that were previously active in global clinical trials. had been damaged or destroyed in the conflict.

The US FDA has approved Anbogen Therapeutics’ IND application for the oral HDAC1/2/3 inhibitor ABT-301 in preparation for a Phase I/II trial.